ASSESSMENT OF CARDIAC AMYLOIDOSIS BY USING 18F-SODIUM FLUORIDE PET/MR IMAGING.

Similar documents
IMAGING IN CARDIAC AMYLOIDOSIS ; TRENDS IN DIAGNOSIS AND GUIDING THERAPY

Update in Nuclear Imaging of Amyloidosis and Sarcoidosis

CARDIAC AMYLOIDOSIS IMAGING ERIC MARTIN MD

Diagnostic approach to cardiac amyloidosis: A case report

C. Quarta, L. Obici, S. Longhi, S. Perlini, A. Milandri, F. Del Corso, F. Perfetto, F. Cappelli, G. Merlini, C. Rapezzi

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC

: A Study Examining the Prevalence of Transthyretin Mutations in Subjects Suspected of Having Cardiac Amyloidosis

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

Clinical history. 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Cardiac catheterization: no CAD

Multiparametric T1, T2 and T2* MR Imaging

CT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea

Restrictive Cardiomyopathy

Cardial MRI; Approaching the Level of Gold Standard for Viability Assessment

Whole body amyloid deposition imaging by 123I-SAP scintigraphy van Rheenen, Ronald; Glaudemans, Andor; Hazenberg, Bouke

The Value of Stress MRI in Evaluation of Myocardial Ischemia

Hereditary ATTR (hattr) Amyloidosis: Cardiomyopathy An Overview. Identifying the link can lead to a crucial diagnosis

Imaging Saves Lives: An Evidence-Based Choice of Modality Magnetic Resonance Imaging

THE NEW PLACE OF CARDIAC MRI IN AERONAUTICAL FITNESS

Understanding Cardiac Amyloidosis: Role of Cardiac Magnetic Resonance Imaging

Role of CMR in heart failure and cardiomyopathy

Cardiovascular manifestations of HIV

Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures?

Le FDG dans l évaluation de la viabilité : Quelle place par rapport aux autres traceurs?

Constrictive/Restrictive Cardiomyopathies: Diagnosis and Management Update; Radiation Induced Heart Disease. Alexander (Sandy) Dick, MD

The Role of Nuclear Imaging in Heart Failure

Technetium-99m Pyrophosphate Scintigraphic Finding in Cardiac Amyloidosis: A Case Report

Perfusion, Viability, Edema and Hemorrhage: How it Can (and Should) Change Clinical Practice. Rohan Dharmakumar, Ph.D.

Progress in the Treatment of Cardiac Amyloidosis

Klinische Anwendung und neue Entwicklungen: Welches Verfahren für welche Indika:on? Kardiales MR. 17. Zürcher Herzkurs

27-year-old professionnal rugby player: asymptomatic

What s New in Cardiac MRI

Imaging and heart failure

156 JACC: CARDIOVASCULAR IMAGING, VOL. 3, NO. 2, 2010 ABBREVIATIONS AND ACRONYMS BNP B-type natriuretic peptide CA cardiac amyloidosis CMR cardiac mag

Assessment Of Myocardial Viability

Previous MI with no intervention

European Journal of Hybrid Imaging. Stuart C. Ramsay 1,2*, Karen Lindsay 1, William Fong 1, Shaun Patford 1, John Younger 3 and John Atherton 3,4

CNR, G. Monasterio Foundation, Clinical Physiology Institute Pisa

ORIGINAL ARTICLE. Umeå, Sweden b Heart Centre, Department of Surgical and Perioperative Sciences, Clinical Physiology, Umeå

Echocardiographic Assessment of the Cardiac Amyloidoses

Gated blood pool ventriculography: Is there still a role in myocardial viability?

PET/CT and PET/MR of Cardiac Tumors

Recognizing and Treating Amyloidosis in Heart Failure Patients. Denise Barnard, M.D., F.A.C.C. 18 th Annual HF Symposium

Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity

Amyloidosis. Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London

New approaches in amyloidosis. Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London

Advanced MR Imaging in Myocarditis

Rational use of imaging for viability evaluation

Cardiac Sarcoidosis. Millee Singh DO Non Invasive Cardiology First Coast Heart and Vascluar

A Case of Impending Cardiac Tamponade Caused by Effusive Constrictive Pericarditis

ESC 2018 Tafamidis Analyst Briefing. August 27, 2018

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

Molecular Imaging of Coronary Plaques

CMR characteristics in cardiac amyloidosis

The Athletic Heart Takes Shape: Overview of Cardiac Remodeling Rory B. Weiner, MD

Case based learning: CMR in Heart Failure

The role of Magnetic Resonance Imaging in the diagnosis of viability & Coronary Artery Disease

Hereditary ATTR (hattr) Amyloidosis: Polyneuropathy An Overview. Identifying the link can lead to a crucial diagnosis

Cardiac MRI: Clinical Application to Disease

Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute

Cardiac MRI: Cardiomyopathy

Cardiac magnetic resonance imaging of systemic amyloidosis patients with normal left ventricular ejection fraction: An initial study

IRM cardiaque en cancérologie: le rôle du radiologue

ORIGINAL ARTICLE. 123 I-MIBG scintigraphy reflects cardiomyopathy

Current Indications for Cardiac MRI: What You See is What You Get?

JACC: CARDIOVASCULAR IMAGING VOL. 8, NO. 1, 2015 ª 2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN X/$36.00

EAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers

A case of cardiac sarcoidosis mimicking cardiac amyloidosis on cardiovascular magnetic resonance

HFPEF Echo with Strain vs. MRI T1 Mapping

The use of Cardiac CT and MRI in Clinical Practice

HYPERTROPHY: Behind the curtain. V. Yotova St. Radboud Medical University Center, Nijmegen

Noninvasive Diagnosis of Biopsy-Proven Cardiac Amyloidosis

Focus on cardiac amyloidosis. Overview. Others cause chamber enlargement and wall thinning. ECG or echo often doesn t fit the usual etiologies

Cardiomyopathy. Cardiomyopathies HOCM. Hypertrophic Obstructive Cardiomyopathy. Systolic Anterior Movement (SAM) of Mitral Valve (Venturi Effect) Cine

A classic case of amyloid cardiomyopathy

3/27/2014. Introduction.

XVth Balkan Congress of Radiology Danubius Hotel Helia, October 2017, Budapest, Hungary

Amyloid Transthyretin (ATTR) Amyloidosis AN OVERVIEW

Myocardial viability testing. What we knew and what is new

Amyloidosis: What to do and how to diagnose: An Update 2017

CLINICAL/THERAPEUTIC APPROACHES TO THREE SPECIFIC CARDIOMYOPAHIES: MYOCARDITIS, AMYLOIDOSIS, AND NON-COMPACTION

Cardiac MRI: Clinical Application to Disease

How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto

PET myocard perfusion & viability Riemer Slart

Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future

DELAYED ENHANCEMENT IMAGING IN CHILDREN

Utility of Echocardiography

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

The aorta is an integral part of the cardiovascular system and should not be considered as just a conduit for blood supply from the heart to the

Methodological aspects of quantitative cardiac molecular imaging

Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology

Stress only Perfusion Imaging

Qualitative and Quantitative Assessment of Perfusion

Stepwise Approach for the Diagnosis of Amyloid Heart Disease

Systemic Amyloidosis Insights by Cardiovascular Magnetic Resonance

CARDIAC PET PERFUSION IMAGING with RUBIDIUM-82

Cardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018

Apport de la TEP au FDG dans les infections cardiovasculaires François Rouzet, MD, PhD

Transcription:

ASSESSMENT OF CARDIAC AMYLOIDOSIS BY USING 18F-SODIUM FLUORIDE PET/MR IMAGING. R. Abgral, M.Trivieri, M. Dweck, P. Robson, N. Karakatsanis, A. Lala, J. Contreras, R. Gopalan, P. Gorevic, V. Fuster, J. Contreras, J. Kovacic, Z. Fayad. Journées Francophones de Médecine Nucléaire Nantes 2017

Rationale Cardiac amyloidosis (CA) Deposition of insoluble fibrils in the myocardium Falk et al. N J Eng Med 1999 Restrictive cardiomyopathy Conduction abnormalities, arrhythmias Heart failure 2 most frequent types Falk et al. Prog Cardiovasc Dis 2011 Transthyrétine (ATTR) Hereditary or Mutated : Ile68Leu, Val30Met Senile or Wild type Acquired monoclonal immunoglobulin light-chain (AL) 2

Rationale Non invasive diagnostic modalities Echocardiography MRI Falk et al. Cardiovasc Imaging 2016 Myocardial wall and valvular thickening Granular sparkling appearance Pericardial effusion Banypersad et al. Eur Heart J 2015 Fontana et al. JACC Cardiovasc Imaging 2014 Diffuse subendocardial or transmural LGE Abnormalities in T1 mapping None of them can distinguish ATTR and AL forms Real challenge for treatment management and prognosis 3

Rationale 99m-Tc-diphosphonate SPECT Differentiation ATTR vs. AL forms Diffuse uptake in ATTR Perugini et al. JACC 2005 Rapezzi et al. Eur J Nucl Med Mol Imaging 2011 AL ATTR 4

Rationale 99m-Tc-diphosphonate SPECT Differentiation ATTR vs. AL forms Prognostic information in ATTR Heart retention ratios Rapezzi et al. JACC Imaging 2011 Galat et al. Amyloid 2015 5

Rationale 18F-NaF PET/CT Controversial results in two series of case report Higher uptake in ATTR vs AL Van Der Gucht et al. J Nucl Cardiol 2015 No uptake in ATTRm or ATTRwt forms? Gagliardi et al. J Nucl Cardiol 2017 6

Aim To assess usefulness of a single low radiation scan using 18F-Sodium Fluoride PET/MR imaging for: Diagnosis of cardiac amyloidosis Differentiation of ATTR and AL forms 7

Methods Population Consecutive patients Grant NIH/NHLBI R01HL071021 Mount Sinai Hospital of New York Histologically proven amyloidosis Control group of volunteers Imaging procedure PET/MR Biograph mmr system (Siemens ) 90min dynamic PET after 5 MBq/Kg NaF 4 classes Dixon μmap T1 weighted LGE sequences after 30ml Gadolinium injection 8

Methods Image analysis PET static SUVmax TBRmax Highest uptake (green) corrected for blood pool SUVmean in RV (red) PET PET/MR 9

Methods 33min 68min 23min 58min 13min 48min Image analysis PET static SUVmax TBRmax PET dynamic TBRmean CNR 10

Methods Image analysis MRI LGE Wall thickening LVEF LGE MRI T1 values in pre-/post-contrast mapping Pre T1 Post T1 11

Results Population (n=18) November 2015-December 2016 9 cardiac amyloidosis 6 ATTR 2 Ile68Leu mutated 4 wild type 3 AL Characteristics Amyloid (n=9) Controls (n=9) Age (mean SD) 66.3 ± 8.9 56.3 ± 10.7 Gender (M/F) 8/1 4/5 Symptoms (n,%) 9 (100) 0(0) ECG abnormalities (n,%) 6 (67) 0(0) 9 control subjects Healthy volunteers 12

Results PET/MR analysis Visual No LGE or abnormal NaF uptake in control patients Characteristic LGE in all CA with different PET patterns Low NaF uptake < BP level in AL Moderate NaF uptake BP level in ATTR 13

Results PET/MR analysis Visual Quantitative ATTR (n=6) AL (n=3) p value PARAMETERS (mean+/-sd) SUVmax 1.3 ± 0.3 1.2 ± 0.1 0.526 TBRmax 2 1,8 p = 0.0028 p = 0.0001 p = 0.046 TBRmax 1.3 ± 0.3 0.8 ± 0.1 0.028 1,6 SW thickness (mm) 1.5 ± 0.4 1.5 ± 0.5 0.962 1,4 LVEF (%) 55 ± 6 63 ± 3 0.066 1,2 Pré T1 (ms) 1465 ± 134 1405 ± 26 0.479 Post T1 (ms) 342 ± 63 311 ± 99 0.571 1 0.85 0,8 0,6 0,4 ATTR AL CT 14

Results Dynamic PET analysis 3 significant different patterns of TBRmean Supports previous results TBRmean Min 15

Results 2 1,5 1 0,5 0 Dynamic analysis 3 significant different patterns of TBRmean Supports previous results Highest CNR 60min with TBR plateau Suggests a 60-90min scan window TBR (Myocardium vs. LV blood pool) suggested scan window 0 20 40 60 80 100 TBR (Myocardium vs. LV 10 8 6 4 2 0 Myocardium CNR suggested scan window 0 50 100 Myocardium CNR 16

Examples ATTR SUVmax = 1.7 TBRmax= 1.4 AL SUVmax = 1.1 TBRmax= 0.7 Control SUVmax = 0.8 TBRmax= 0.7 17

Conclusions Usefulness of NaF PET/MR for both diagnosis of cardiac amyloidosis (LGE, T1 mapping) and differentiation of AL and ATTR (quantification) within a single scan. Myocardial NaF uptake lower than the blood-pool in healthy volunteers and patients with AL. By contrast increased in ATTR with a TBRmax=0.85 cut-off appearing to provide discrimination. 18

Thanks for attention 19